Method for treating multiple sclerosis
The present invention is directed to a method for treating multiple sclerosis by administering dapansutrile to a subject in need thereof. A preferred route of administration is oral administration.
1. A method for treating multiple sclerosis, comprising the step of administering to a subject in need thereof an effective amount of dapansutrile.
2. The method according to claim 1 , wherein said compound is administered by systemic administration.
3. The method according to claim 1 , wherein said compound is administered by oral administration.
4. The method according to claim 1 , wherein said treatment is prophylactic treatment before the onset of multiple sclerosis.
5. The method according to claim 1 , wherein said treatment is therapeutic treatment after the onset of multiple sclerosis.
6. The method according to claim 1 , wherein said multiple sclerosis is relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, or progressive relapsing multiple sclerosis.
7. The method according to claim 6 , wherein said multiple sclerosis is relapsing-remitting multiple sclerosis.
8. The method according to claim 7 , wherein dapansutrile is administered for a period of time sufficient to achieve one or more of changes selected from the group consisting of: (a) reduced frequency of relapse in the subject, (b) reduced probability of relapse in the subject, (c) reduced annualized relapse rate in the subject, (d) reduced risk of disability progression in the subject, (e) reduced number of new or newly enlarging T2 lesions in the subject, (f) reduced number of new non-enhancing T1 hypointense lesions in the subject, and (g) reduced number of gadolinium (Gd+) lesions in the subject.
9. The method according to claim 7 , wherein dapansutrile is administered for a period of time sufficient to achieve one or more of changes selected from the group consisting of: (a) reduced annualized relapse rate of at least 30%; (b) reduced risk of disability progression of at least 30%; and (c) reduced number of new or newly enlarging T2 lesions of at least 65% in the subject.